Array Biopharma (ARRY) Tops Q1 EPS by 1c
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $7.69 -2.66%
Revenue Growth %: -11.6%
Financial Fact:
Total operating expenses: 63.27M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: -11.6%
Financial Fact:
Total operating expenses: 63.27M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q1 EPS of ($0.21), $0.01 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $6.07 million versus the consensus estimate of $6.35 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
- Micron Technology (MU) PT Raised to $1,100 at Goldman Sachs
- Colony Bankcorp to acquire First Reliance in $163M stock-and-cash deal
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
